6 results on '"Kerkmeijer, Linda G.W."'
Search Results
2. Urethral and bladder dose–effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial.
- Author
-
Groen, Veerle H., van Schie, Marcel, Zuithoff, Nicolaas P.A., Monninkhof, Evelyn M., Kunze-Busch, Martina, de Boer, Johannes C.J., van der Voort van Zijp, Jochem, Pos, Floris J., Smeenk, Robert Jan, Haustermans, Karin, Isebaert, Sofie, Draulans, Cédric, Depuydt, Tom, Verkooijen, Helena M., van der Heide, Uulke A., and Kerkmeijer, Linda G.W.
- Subjects
- *
EXTERNAL beam radiotherapy , *BLADDER , *PROSTATE cancer , *CANCER radiotherapy , *URINARY incontinence - Abstract
• Dose to the bladder and urethra is related to GU toxicity. • Focal boost treatment plans should include a urethral dose constraint. • Urethral dose-effect relations for hypofractionated schemes should be analyzed. The FLAME trial (NCT01168479) showed that by adding a focal boost to conventional fractionated EBRT in the treatment of localized prostate cancer, the five-year biochemical disease-free survival increased, without significantly increasing toxicity. The aim of the present study was to investigate the association between radiation dose to the bladder and urethra and genitourinary (GU) toxicity grade ≥2 in the entire cohort. The dose–effect relations of the urethra and bladder dose, separately, and GU toxicity grade ≥2 (CTCAE 3.0) up to five years after treatment were assessed. A mixed model analysis for repeated measurements was used, adjusting for age, diabetes mellitus, T-stage, baseline GU toxicity grade ≥1 and institute. Additionally, the association between the dose and separate GU toxicity subdomains were investigated. Dose-effect relations were observed for the dose (Gy) to the bladder D2 cm3 and urethra D0.1 cm3, with adjusted odds ratios of 1.14 (95% CI 1.12–1.16, p < 0.0001) and 1.12 (95% CI 1.11–1.14, p < 0.0001), respectively. Additionally, associations between the dose to the urethra and bladder and the subdomains urinary frequency, urinary retention and urinary incontinence were observed. Further increasing the dose to the bladder and urethra will result in a significant increase in GU toxicity following EBRT. Focal boost treatment plans should incorporate a urethral dose-constraint. Further treatment optimization to increase the focal boost dose without increasing the dose to the urethra and other organs at risk should be a focus for future research, as we have shown that a focal boost is beneficial in the treatment of prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Anorectal dose–effect relations for late gastrointestinal toxicity following external beam radiotherapy for prostate cancer in the FLAME trial.
- Author
-
Groen, Veerle H., Zuithoff, Nicolaas P.A., van Schie, Marcel, Monninkhof, Evelyn M., Kunze-Busch, Martina, de Boer, Hans C.J., van der Voort van Zyp, Jochem, Pos, Floris J., Smeenk, Robert Jan, Haustermans, Karin, Isebaert, Sofie, Draulans, Cédric, Depuydt, Tom, Verkooijen, Helena M., van der Heide, Uulke A., and Kerkmeijer, Linda G.W.
- Subjects
- *
EXTERNAL beam radiotherapy , *PROSTATE cancer , *CARDIOVASCULAR diseases , *FLAME , *CANCER radiotherapy , *RADIATION doses - Abstract
• A higher radiation dose to the anorectum is associated with increased overall GI toxicity. • Increasing the dose to the anorectum should be weighed against the benefit of focal dose escalation. • Further increasing the dose to the tumor without increasing the anorectal dose should be explored. The phase III FLAME trial (NCT01168479) showed an increase in five-year biochemical disease-free survival, with no significant increase in toxicity when adding a focal boost to external beam radiotherapy (EBRT) for localized prostate cancer [Kerkmeijer et al. JCO 2021]. The aim of this study was to investigate the association between delivered radiation dose to the anorectum and gastrointestinal (GI) toxicity (grade ≥2). All patients in the FLAME trial were analyzed, irrespective of treatment arm. The dose–effect relation of the anorectal dose parameters (D2cm3 and D50%) and GI toxicity grade ≥2 in four years of follow-up was assessed using a mixed model analysis for repeated measurements, adjusted for age, cardiovascular disease, diabetes mellitus, T-stage, baseline toxicity grade ≥1, hormonal therapy and institute. A dose–effect relation for D2cm3 and D50% was observed with adjusted odds ratios of 1.17 (95% CI 1.13–1.21, p < 0.0001) and 1.20 (95% CI 1.14–1.25, p < 0.0001) for GI toxicity, respectively. Although there was no difference in toxicity between study arms, a higher radiation dose to the anorectum was associated with a statistically significant increase in GI toxicity following EBRT for prostate cancer. This dose–effect relation was present for both large and small anorectal volumes. Therefore, further increase in dose to the anorectum should be weighed against the benefit of focal dose escalation for prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Comparing adaptation strategies in MRI-guided online adaptive radiotherapy for prostate cancer: Implications for treatment margins.
- Author
-
Dassen, Mathijs G., Janssen, Tomas, Kusters, Martijn, Pos, Floris, Kerkmeijer, Linda G.W., van der Heide, Uulke A., and van der Bijl, Erik
- Subjects
- *
PROSTATE cancer , *CANCER radiotherapy , *SEMINAL vesicles , *CANCER treatment , *PROSTATE - Abstract
• Daily re-delineation of the prostate does not reduce the required PTV margin. • Daily re-delineation of the seminal vesicles reduces the required PTV margin. • GTV coverage improves when correcting for both CTV translations and rotations. To quantify the difference in accuracy of adapt-to-position (ATP), adapt-to-rotation (ATR) and adapt-to-shape (ATS) workflows used in MRI-guided online adaptive radiotherapy for prostate carcinoma (PCa) by evaluating the margins required to accommodate intra-fraction motion of the clinical target volumes for prostate (CTVpros), prostate including seminal vesicles (CTVpros + sv) and gross tumor volume (GTV). Clinical delineations of the CTVpros, CTVpros + sv and GTV of 24 patients with intermediate- and high-risk PCa, treated using ATS on a 1.5 T MR-Linac, were used for analysis. Delineations were available pre- and during beam-on. To simulate ATP and ATR workflows, we automatically generated the structures associated with these workflows using rigid transformations from the planning-MRI to the daily online MRIs. Clinical GTVs were analyzed as ATR GTVs and only ATP GTVs were simulated. Planning target volumes (PTVs) were generated with isotropic margins ranging 0.0–5.0 mm. The volumetric overlap was calculated between these PTVs and their corresponding clinical delineation on the MRI acquired during beam-on and averaged over all treatment fractions. The PTV margin required to cover > 95% of the CTVpros was equal (2.5 mm) for all workflows. For the CTVpros + sv, this margin increased to 5.0, 4.0 and 3.5 mm in the ATP, ATR and ATS workflow, respectively. GTV coverage improved from ATP to ATR for margins up to 4.0 mm. ATP, ATR and ATS workflows ensure equal coverage of the CTVpros for the current clinical margins. For the CTVpros + sv, ATS showed optimal performance. GTV coverage improves by additional adaptations to prostate rotations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial.
- Author
-
Monninkhof, Evelyn M., van Loon, Juliette W.L., van Vulpen, Marco, Kerkmeijer, Linda G.W., Pos, Floris J., Haustermans, Karin, van den Bergh, Laura, Isebaert, Sofie, McColl, Gill M., Smeenk, Robert Jan, Noteboom, Juus, Walraven, Iris, Peeters, Petra H.M., and van der Heide, Uulke A.
- Subjects
- *
PROSTATE cancer treatment , *CANCER radiotherapy , *DISEASE prevalence , *GENERALIZED estimating equations , *RANDOMIZED controlled trials - Abstract
Purpose To compare toxicity rates in patients with localized prostate cancer treated with standard fractionated external beam radiotherapy (EBRT) with or without an additional integrated boost to the macroscopically visible tumour. Material and methods FLAME is a phase 3 multicentre RCT (NCT01168479) of patients with pathologically confirmed localized intermediate or high-risk prostate cancer. The standard treatment arm ( n = 287) received a dose to the entire prostate of 77 Gy in 35 fractions. The dose-escalated treatment arm ( n = 284) received 77 Gy in 35 fractions to the entire prostate, with an integrated boost up to 95 Gy to the multi-parametric MRI-defined (macroscopic) tumour within the prostate. Treatment related toxicity was measured using the CTCAE version 3.0. Grade 2 or worse GU or GI events up to two years were compared between groups by presenting proportions and by Generalized Estimating Equations (GEE) analyses for repeated measures. Results Ninety percent of the 571 men randomly assigned between September 2009 and January 2015 had high-risk disease (Ash 2000), of whom nearly 66% were prescribed hormonal therapy up to three years. Median follow-up was 55 months at the time of this analysis. Toxicity prevalence rates for both GI and GU increased until the end of treatment and regressed thereafter, with no obvious differences across treatment groups. Late cumulative GI toxicity rates were 11.1% and 10.2% for the standard and dose-escalated group, respectively. These rates were 22.6% and 27.1% for GU toxicity. GEE analyses showed that both GU toxicity and GI toxicity (≥grade 2) up to two years after treatment were similar between arms (OR 1.02 95%CI 0.78–1.33p = 0.81 and (OR 1.19 95%CI 0.82–1.73p = 0.38), respectively. Conclusions In intermediate- and high-risk prostate cancer patients, focal dose escalation integrated with standard EBRT did not result in an increase in GU and GI toxicity when compared to the standard treatment up to two years after treatment. This suggests that the described focal dose escalation technique is safe and feasible. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Prostate tumor delineation using multiparametric magnetic resonance imaging: Inter-observer variability and pathology validation.
- Author
-
Steenbergen, Peter, Haustermans, Karin, Lerut, Evelyne, Oyen, Raymond, De Wever, Liesbeth, Van den Bergh, Laura, Kerkmeijer, Linda G.W., Pameijer, Frank A., Veldhuis, Wouter B., van der Voort van Zyp, Jochem R.N., Pos, Floris J., Heijmink, Stijn W., Kalisvaart, Robin, Teertstra, Hendrik J., Dinh, Cuong V., Ghobadi, Ghazaleh, and van der Heide, Uulke A.
- Subjects
- *
PROSTATE tumors treatment , *MAGNETIC resonance imaging , *RADIATION doses , *CANCER radiotherapy , *HEALTH outcome assessment , *ONCOLOGY - Abstract
Background and purpose Boosting the dose to the largest (dominant) lesion in radiotherapy of prostate cancer may improve treatment outcome. The success of this approach relies on the detection and delineation of tumors. The agreement among teams of radiation oncologists and radiologists delineating lesions on multiparametric magnetic resonance imaging (mp-MRI) was assessed by measuring the distances between observer contours. The accuracy of detection and delineation was determined using whole-mount histopathology specimens as reference. Material and methods Six observer teams delineated tumors on mp-MRI of 20 prostate cancer patients who underwent a prostatectomy. To assess the inter-observer agreement, the inter-observer standard deviation (SD) of the contours was calculated for tumor sites which were identified by all teams. Results Eighteen of 89 lesions were identified by all teams, all were dominant lesions. The median histological volume of these was 2.4 cm 3 . The median inter-observer SD of the delineations was 0.23 cm. Sixty-six of 69 satellites were missed by all teams. Conclusion Since all teams identify most dominant lesions, dose escalation to the dominant lesion is feasible. Sufficient dose to the whole prostate may need to be maintained to prevent under treatment of smaller lesions and undetected parts of larger lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.